Susan M. O'Brien MD

Hematologic Oncology

Associate Director for Clinical Sciences, Chao Family Comprehensive Cancer Center, UCI Health

101 The City Drive SouthBldg 23 RM 403Orange, CA 92868
Phone+1 714-456-8000
Fax+1 714-456-3810

Dr. O'Brien is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Brien's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1987
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1980 - 1983
Rutgers New Jersey Medical SchoolClass of 1980

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2018 - 2028
TX State Medical License 1987 - 2024
NJ State Medical License 1983 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Giants of Cancer Care: Leukemia MJH Life Sciences, 2021
America's Top Doctors for Cancer Castle Connolly, 2005-2019
America's Top Doctors Castle Connolly, 2003-2019

Clinical Trials

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
COMPLETED
PHASE2
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
COMPLETED
PHASE2
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
COMPLETED
PHASE2

Publications & Presentations

PubMed

Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
Susan O'Brien
Clinical Advances in Hematology & Oncology. 2021-10-01
20 citations
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propen...
Koji Sasaki, Hagop M. Kantarjian, Kiyomi Morita, Nicholas J. Short, Marina Konopleva
Cancer. 2021-09-15
31 citations
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.
Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio
Blood. 2021-08-18

Abstracts/Posters

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Discussing Treatment of CLL in the Era of Novel Therapeutic AgentsDecember 3rd, 2019
Improving Outcomes in Older Patients with Newly Diagnosed ALLMay 9th, 2019
T2D'S Tie to Pancreatic Ca: Oncotherapy Network & Cancer NetworkFebruary 14th, 2017